A new ADC biotech looks to revive secretive platform, secures Big VC backing

Paul Schloesser

Associate Editor

With many companies working with antibody-drug conjugates in cancer, the newest one has two substantial backers and is looking to revitalize an old platform. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A new ADC biotech looks to revive secretive platform, secures Big VC backing

Paul Schloesser

Associate Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Omada Health is going public on Friday at a $1.1B valuation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

A new ADC biotech looks to re­vive se­cre­tive plat­form, se­cures Big VC back­ing

Associate Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A new ADC biotech looks to revive secretive platform, secures Big VC backing